[5/19]
WHO ±Û·Î¹ú COVID-19 ¿ªÇÐ µ¿Çâ
(COVID-19 Global Epidemiological Update )
Coronavirus Disease 2019 (COVID-19) Highlights »óȲº¸°í
¼¼°èº¸°Ç±â±¸ COVID-19 Highlights
ÁÖ¿ä ±¹°¡º° COVID-19 È®ÁøÀÚ, Ä¡¸í·ü ¹× ¿ÏÄ¡À²(2020.0519)
ÇöÀç Àü¼¼°èÀûÀ¸·Î 214°³±¹¿¡¼ COVID-19·Î ÀÎÇÑ È®ÁøÀÚ´Â4,618,821 cases ¸í, »ç¸ÁÀÚ ´Â 311,847¸íÀ¸·Î ÇöÀç±îÁö Ä¡¸íÀ²(CFR)Àº 6.60%¸¦ ³ªÅ¸³»°í ÀÖ´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ ÀÇÇÑ ÁÖ¿ä Áö¿ªº° È®ÁøÀÚ ¹× Ä¡¸í·ü(CFR)Àº ¾Æ·¡¿Í °°´Ù.
Ç¥ 1 ) ¼¼°è Áö¿ªº° COVID-10 È®ÁøÀÚ, Ä¡¸í·ü (WHO Situation Report-119)
±¸ºÐ
|
À¯·´
|
¾Æ¸Þ¸®Ä«
|
µ¿ºÎÁöÁßÇØ
|
¼ÅÂÆò¾ç
|
µ¿³²¾Æ½Ã¾Æ
|
¾ÆÇÁ¸®Ä«
|
È®ÁøÀÚ(¸í)
|
1,890,467
|
2,017,811
|
338,560
|
168,515
|
141,593
|
61,163
|
»ç¸ÁÀÚ(¸í)
|
167,173
|
121,609
|
9,979
|
6,743
|
4,582
|
1, 748
|
Ä¡¸í·ü(CFR)
|
8.84%
|
6.02%
|
2.95
|
4.0%
|
3.23
|
2.86
|
±×¸² 1) COVID-19 È®Áø ±¹°¡ ¹× Áö¿ªº° È®Áø »ç·Ê(2020³â5¿ù18ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report -119 [¹Ù·Î°¡±â]
Ç¥ 2) ±¹°¡ ¹× Áö¿ªº° COVID-19 È®Áø ÇöȲ(2020³â5¿ù18ÀÏÀÚ WHO º¸°í)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 119
±×¸² 3) COVID-19 È®Áø ¿ªÇа(³¯Â¥º°, Áö¿ªº° 2020³â 5¿ù18ÀÏÀÚ)
Source: WHO Coronavirus disease 2019 (COVID-19) Situation Report 119 [¹Ù·Î°¡±â]
[Ãֽŵ¿Çâ] Coronavirus 2019 (COVID-19)] Highlights
F1. [±¹³»Ç÷ÀåÄ¡·á¼º°ø] COVID-19: ¿ÏÄ¡ÀÚ Ç÷ÀåÄ¡·á(Convalescent Plasma)
±¹³» ¼¼ºê¶õ½ºº´¿ø ¿¬±¸ÆÀÀº ¿ÏÄ¡ÀÚ Ç÷Àå(Convalescent Plasma) Ä¡·á¹æ¹ýÀ¸·Î ÀÓ»ó¿¡¼ Coronavirus disease 2019 (COVID-19)ÀÇ ¿ÏÄ¡ »ç·Ê¸¦ º¸°íÇß´Ù. ÀÌ°ÍÀº Çѱ¹¿¡¼ COVID-19¿¡ ´ëÇÑ ¿ÏÄ¡ÀÚ Ç÷Àå Ä¡·á¿¡ ´ëÇÑ Ã¹ ¹ø° ÀÓ»ó ¿ÏÄ¡»ç·ÊÀÌ´Ù. [»ó¼¼ ´õº¸±â]
F2. COVID-19 Ä¡·áÁ¦ ±ÝÁö :À̺ÎÇÁ·ÎÆæ(Ibuprofen), ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁ¦(NSAIDs)
ÀÇÇÐ Àú³Î ¶õ¼Â(The Lancet Respiratory Medicine)Àº À̺ÎÇÁ·ÎÆæÀ» Æ÷ÇÔÇÑ ÀϺΠ¾àÇ°ÀÌ °íÇ÷¾ÐÀ̳ª ´ç´¢º´À» ¾Î´Â COVID-19 ȯÀÚ¿¡°Ô À§ÇèÇÒ ¼ö ÀÖ´Ù´Â °¡¼³À» ¹ßÇ¥Çß´Ù. À̺ÎÇÁ·ÎÆæÀº ºñ½ºÅ×·ÎÀ̵强 Ç׿°ÁõÁøÅëÁ¦·Î, ÁøÅëÁ¦³ª ÇØ¿Á¦·Îµµ ¾²ÀδÙ. ‘¶õ¼Â È£Èí±âÀÇÇÐ(Lancet Respiratory Medicine)’¿¡¼ ¸¶ÀÌŬ ·Î½º(Michael Roth) ¹ÙÁ©ÀÇ´ë ±³¼ö´Â À̺ÎÇÁ·ÎÆæÀ» º¹¿ëÇϸé COVID-19ÀÇ ÁÖ¿ä ħÅõ °æ·ÎÀΠǥÀû ´Ü¹éÁú ACE2°¡ ¼¼Æ÷¿¡ °ú´Ù ¹ßÇöµÅ COVID-19ÀÇ ÁßÁõµµ ¶Ç´Â °¨¿° À§ÇèÀ» ³ôÀÏ ¼ö ÀÖÀ½À» ¹àÇû´Ù. [»ó¼¼ ´õº¸±â]
F3. COVID-19 Ä¡·áÁ¦°³¹ß ±Û·Î¹ú Àӻ󿬱¸ ÇÁ·ÎÁ§Æ®ÇöȲ
½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º °¨¿°Áõ(Äڷγª19) Ä¡·áÁ¦ °³¹ßÀ» À§ÇØ Àü¼¼°è°¡ ³ë·ÂÇÏ°í ÀÖ´Â °¡¿îµ¥, ÇöÀç Äڷγª 19 Ä¡·áÁ¦ °³¹ß°ú °ü·Ã ±¹Á¦ÀûÀ¸·Î Àӻ󿬱¸°¡ 335,815°ÇÀÌ ÁøÇà Áß¿¡ ÀÖ´Ù(2020³â 4¿ù 13ÀÏÀÚ µî·ÏÇöȲ). ¹Ì±¹ ±¹¸³º¸°Ç¿ø NIH ClinicalTrials.gov¿¡ µî·ÏµÇ¾î ÁøÇàÇÏ°í ÀÖ´Â COVID-19 °ü·Ã Àӻ󿬱¸´Â 300¿©°Ç ÀÌ»óÀÌ ÁøÇà Áß¿¡ ÀÖÀ¸¸ç, ¼¼°èº¸°Ç±â±¸(WHO)±¹Á¦Àӻ󿬱¸µî·Ï Ç÷§Æû(World Health Organization's International Clinical Trials Registry Platform, WHO ICTRP)¿¡¼´Â 590°ÇÀÇ ÇÁ·ÎÁ§Æ®°¡ ÇöÀç Àӻ󿬱¸ Áß¿¡ ÀÖ´Ù. [»ó¼¼ ´õº¸±â]
F4. COVID-19 ½ÉÇ÷°üÁúȯ ¾à¹°Ä¡·á- ÀáÀçÀû À§Çؼº°ú »ç¸Á·ü ¿äÀÎ ¿¬±¸(Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19): Angiotensin-converting–enzyme (ACE) inhibitors & angiotensin-receptor blockers (ARBs)
º» ¿¬±¸´Â The New England Journal of Medicine 2020³â 5¿ù 1ÀÏÀÚ ¹ßÇ¥µÈ COVID-19 ½ÉÇ÷°üÁúȯÀÇ ¾à¹°Ä¡·á- Angiotensin-converting–enzyme (ACE) inhibitors¿Í Angiotensin-receptor blockers (ARBs) »ç¿ë¿¡ ´ëÇÑ ÀáÀçÀû À§Çؼº Æò°¡¿Í »ç¸Á·ü °ü·Ã¿äÀÎ ¿¬±¸ÀÌ´Ù.
º´¿ø ³» »ç¸ÁÀ² Áõ°¡¿Í °ü·ÃÀÖ´Â µ¶¸³¿äÀεéÀº ¾Æ·¡¿Í °°´Ù.
1. 65¼¼ ÀÌ»ó ¿¬·É( (mortality of 10.0%, vs. 4.9% among those ≤65 years of age; odds ratio, 1.93; 95% confidence interval [CI], 1.60 to 2.41) (65 ¼¼ ¹Ì¸¸ÀÇ »ç¸Á·üÀº 10.0 %, »ç¸Á·üÀº 4.9 %)
2. °ü»óµ¿¸Æ Áúȯ(10.2%, vs. 5.2% among those without disease; OR, 2.70; 95% CI, 2.08 to 3.51)
3. ½ÉºÎÀü(15.3%, vs. 5.6% among those without heart failure; OR 2.48; 95% CI, 1.62 to 3.79)
4. ½ÉÀåºÎÁ¤¸Æ(11.5%, vs. 5.6% among those without arrhythmia; OR, 1.95; 95% CI, 1.33 to 2.86)
5. ¸¸¼ºÆó¼â¼ºÆóÁúȯ(14.2%, vs. 5.6% among those without disease; OR, 2.96; 95% CI, 2.00 to 4.40)
6. ÇöÀç Èí¿¬(9.4%, vs. 5.6% among former smokers or nonsmokers; OR, 1.79; 95% CI, 1.29 to 2.47)
¾à¹°Ä¡·á¿Í »ç¸Á·ü°úÀÇ °ü·ÃÀ» ºÐ¼®ÇÑ °á°ú, ACE inhibitors (2.1% vs. 6.1%; OR, 0.33; 95% CI, 0.20 to 0.54) »ç¿ëÀ̳ª, ARB(6.8% vs. 5.7%; OR, 1.23; 95% CI, 0.87 to 1.74) ¾à¹°Ä¡·á´Â º´¿ø³»¿¡¼ »ç¸ÁÀ§ÇèÀ» Áõ°¡½ÃÅ°´Â °Í°ú °ü·ÃÀÌ ¾ø´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. [¿ø¹®º¸±â]
Ç¥ 3) Coronavirus disease (COVID-19) ÃֽŠÇмúÁ¤º¸ »çÀÌÆ® ¹Ù·Î°¡±â
Ç¥4) Coronavirus disease (COVID-19) ±¹³» ¹× ±¹¿Ü ÃÖ±Ù ¾÷µ¥ÀÌÆ® Á¤º¸ ¹Ù·Î°¡±â
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ Á¦°ø
References
WHO, Coronavirus disease 2019 (COVID-19) Situation Report 119 (May 19, 2020) [¹Ù·Î°¡±â]
Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 (May 01, 2020). The New England Journal of Medicine [¹Ù·Î°¡±â]
WHO Officials Discuss the Weather Question (March 05, 2020) [¹Ù·Î°¡±â]
ÀÇ°úÇבּ¸Á¤º¸¼¾ÅÍ(MedRIC). COVID-19 outbreak: Comparison of: SARS, MERS (March 05, 2020). [¹Ù·Î°¡±â]
Will Warm Weather Curb Coronavirus? What the Experts Say, Ari Altstedter & John Lauerman (March 12, 2020), Bloomberg Quicktake [¹Ù·Î°¡±â]
Revised U.S. Surveillance Case Definition for Severe Acute Respiratory Syndrome (SARS) and Update on SARS Cases --- United States and Worldwide, December 2003 [¹Ù·Î°¡±â]
JAMA COVID-19 Resource Center, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention JAMA. Published online February 24, 2020. [¹Ù·Î°¡±â]
¸Þ¸£½º (Middle East Respiratory Syndrome Coronavirus: MERS) Áúº´°ü¸®º»ºÎ [¹Ù·Î°¡±â]
WHO, Severe Acute Respiratory Syndrome (SARS). [¹Ù·Î°¡±â]
WHO, Coronavirus, [¹Ù·Î°¡±â]
The New York Times How Bad Will the Coronavirus Outbreak Get? Here Are 6 Key Factors [¹Ù·Î°¡±â]